Shares of 10x Genomics Inc. rose by 9.43 percent, reaching a closing price of approximately $45.71 on Tuesday, July 14, 2026. The increase follows a series of upgraded price targets from major financial institutions and the announcement of a new research collaboration.
The company entered a multi-year agreement with the Cleveland Clinic to utilize its Flex Apex, Xenium, and Atera platforms for advanced bladder cancer biomarker research. This partnership places 10x Genomics technology directly into high-end oncology studies, signaling institutional validation of the company's diagnostic tools.
Several Wall Street analysts adjusted their valuations for the stock. Barclays raised its price target from $30 to $40 while maintaining an Overweight rating, noting improving sentiment in the life science tools sector and potential for second-quarter earnings to meet or exceed expectations. Citi increased its target significantly from $24 to $45, though it kept a Neutral rating, indicating both upside potential and caution.
Morgan Stanley also raised its target to $37 from $22, sticking with an Equal Weight rating ahead of the next earnings report.
Trading activity showed a steady upward trend throughout the day. After opening around $43 and dipping briefly to $42.37, the stock climbed to close near its daily high. This movement follows a recent surge from a low of the low $30s to the current levels, with traders bidding up the stock ahead of upcoming financial results.
Financially, 10x Genomics reported quarterly revenue of roughly $150.8 million with a gross margin of 69.6 percent. The company posted a negative operating income of approximately $17 million and a net loss of $13.5 million. However, it generated positive operating cash flow of $26.1 million and free cash flow of $24.5 million, supported by disciplined capital expenditures.
The firm holds nearly $490.3 million in cash with minimal long-term debt.
